The North America HLA Typing Market was valued at USD 1,020 Million in 2025 and is expected to reach USD 2,850 Million by 2035, expanding at a CAGR of 9.8% from 2024 to 2035. The market's growth is driven by the increasing incidence of chronic diseases requiring organ transplantation and advancements in genotyping technologies. The market consists of major players such as Thermo Fisher Scientific, Illumina, and QIAGEN, who are continually investing in R&D to improve the precision and scalability of HLA typing solutions.
The economic impact of tariffs on "North America HLA Typing Market".
Market Growth Drivers
Increasing Instances of Organ Transplantation: The growing need for organ transplants in North America has significantly amplified the demand for accurate HLA typing. According to the U.S. Department of Health & Human Services, over 42,000 organ transplants were performed in the U.S. in 2023, a record high. Companies like Thermo Fisher Scientific are leveraging advanced next-generation sequencing (NGS) techniques to provide faster and more accurate HLA matching, which is critical to successful transplantation and minimization of post-transplant complications.
Technological Advancements in Genotyping: Continuous innovation in genotyping platforms has improved the sensitivity and efficiency of HLA typing. Illumina, for instance, introduced the TruSight HLA v2 Sequencing Panel in 2023, which enables high-throughput and high-resolution typing results, reducing turnaround time and enhancing matching accuracy. The integration of automation and AI-driven data analysis by companies such as QIAGEN is further accelerating the adoption of HLA typing technologies across North America.
Market Trends
Adoption of Next-Generation Sequencing for HLA Typing: A significant trend within the North American market is the transition from traditional serological and PCR-based methods to highly accurate next-generation sequencing (NGS). For example, companies like Immucor and Illumina witnessed increased demand for their NGS-based solutions in 2023 due to better resolution of alleles and improved throughput, facilitating more precise donor-recipient matching.
Expansion of Precision Medicine Initiatives: The rising focus on personalized therapies and precision medicine is driving investments in advanced HLA typing for patient stratification and risk assessment. In 2023, Thermo Fisher Scientific partnered with leading academic medical centers in the U.S. to integrate high-resolution HLA typing into oncology and autoimmune disease research, aiming to tailor treatments based on individual genetic profiles.
Market Opportunities
Growing Demand for HLA Typing in Emerging Therapies: The emergence of cell and gene therapies, including CAR-T therapies, necessitates highly accurate HLA typing to prevent immune rejection. Companies like QIAGEN are expanding their HLA testing services to biopharmaceutical clients innovating in the cell therapy space.
Untapped Potential in Population-Wide Genetic Screening: The application of HLA typing for broader population health screening presents significant growth prospects. Leading firms are collaborating with government health agencies to pilot large-scale genetic screening programs targeting inherited disease susceptibility and transplant readiness.
North America HLA Typing Market Revenue (USD Million), 2020-2035
The market revenue chart from 2020 to 2035 demonstrates a strong upward trajectory for the North America HLA Typing Market. Beginning at USD 570 Million in 2020, the market shows consistent year-on-year growth, reaching USD 1,020 Million in 2025 and projected to rise to USD 2,850 Million by 2035. The sharpest acceleration in revenue occurs between 2028 and 2035, attributed to technological breakthroughs and expanded clinical use of HLA typing in personalized medicine and transplantation. This positive trend underscores robust market potential and increasing adoption among healthcare providers and research institutions.
Market Share by Region, 2025 (%)
The 2025 regional market share analysis for the North America HLA Typing Market illustrates that the United States commands the largest share, accounting for 72% of the market, driven by advanced healthcare infrastructure and funding for transplantation research. Canada follows with a 20% share, attributed to its strong research ecosystem and universal healthcare access. Mexico, though smaller in comparison, represents 5% and is witnessing growing investments in genomics. The remaining 3% share is distributed among the Caribbean and Central American territories, which are gradually adopting advanced healthcare solutions. The pie chart highlights the market's heavy concentration in developed regions, yet hints at untapped potential in emerging healthcare markets.
Recent Developments in North America HLA Typing Market (Last 6 Months)
In February 2024, Thermo Fisher Scientific announced the launch of 'Ion Torrent Genexus Integrated Sequencer', a fully automated platform designed to deliver same-day HLA typing results. This innovation streamlines laboratory workflows, reduces personnel requirements, and enhances the overall accuracy and reproducibility of HLA typing, supporting both clinical and research laboratories across North America.
In March 2024, Illumina partnered with the American Society for Histocompatibility and Immunogenetics (ASHI) to initiate a multi-center collaborative study utilizing its TruSight HLA Sequencing Panel. The effort aims to standardize NGS-based HLA typing protocols and set new industry benchmarks for accuracy, efficiency, and cost-effectiveness in transplant and immunogenetics laboratories.
QIAGEN, in April 2024, expanded its QIAseq Targeted DNA Panels product line to incorporate upgraded HLA typing assays that leverage advanced bioinformatics. This move targets the growing cell and gene therapy sectors by providing robust, scalable, and high-resolution solutions for patient eligibility screening, further cementing QIAGEN’s position as a leading provider of molecular diagnostics.
Press Releases